Anixa Biosciences, Inc.
ANIX
$3.09
-$0.17-5.22%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.35% | 19.07% | 12.37% | -10.44% | 12.02% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.71% | -27.94% | 47.03% | -20.53% | -21.32% |
| Change in Net Operating Assets | 828.05% | -158.57% | 127.83% | -151.70% | 260.30% |
| Cash from Operations | 16.94% | -0.53% | 48.24% | -213.27% | 64.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 178.51% | -135.57% | -13.36% | 211.76% | -68.17% |
| Cash from Investing | 178.51% | -135.57% | -13.36% | 211.76% | -68.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.82% | 51,200.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 114.63% | -823.53% | 200.00% | -112.23% | 200.00% |
| Cash from Financing | -81.86% | 10,616.67% | 205.88% | -116.04% | -28.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.52% | -148.42% | 493.12% | -573.91% | -80.00% |